Nature Communications (Jan 2022)
Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction
- Slobodan Vukicevic,
- Andrea Colliva,
- Vera Kufner,
- Valentina Martinelli,
- Silvia Moimas,
- Simone Vodret,
- Viktorija Rumenovic,
- Milan Milosevic,
- Boris Brkljacic,
- Diana Delic-Brkljacic,
- Ricardo Correa,
- Mauro Giacca,
- Manuel Maglione,
- Tatjana Bordukalo-Niksic,
- Ivo Dumic-Cule,
- Serena Zacchigna
Affiliations
- Slobodan Vukicevic
- Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, University of Zagreb School of Medicine
- Andrea Colliva
- Cardiovascular Biology, International Centre for Genetic Engineering and Biotechnology
- Vera Kufner
- Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, University of Zagreb School of Medicine
- Valentina Martinelli
- Molecular Medicine, International Centre for Genetic Engineering and Biotechnology
- Silvia Moimas
- Molecular Medicine, International Centre for Genetic Engineering and Biotechnology
- Simone Vodret
- Cardiovascular Biology, International Centre for Genetic Engineering and Biotechnology
- Viktorija Rumenovic
- Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, University of Zagreb School of Medicine
- Milan Milosevic
- Department for Environmental Health and Occupational and Sports Medicine, University of Zagreb School of Medicine
- Boris Brkljacic
- Department of Diagnostic and Interventional Radiology, University Hospital Dubrava, University of Zagreb School of Medicine
- Diana Delic-Brkljacic
- Department of Cardiology, Clinical Hospital Sisters of Mercy, University of Zagreb School of Medicine
- Ricardo Correa
- Cardiovascular Biology, International Centre for Genetic Engineering and Biotechnology
- Mauro Giacca
- Department of Medicine, Surgery and Health Sciences, University of Trieste
- Manuel Maglione
- Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck
- Tatjana Bordukalo-Niksic
- Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, University of Zagreb School of Medicine
- Ivo Dumic-Cule
- Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, University of Zagreb School of Medicine
- Serena Zacchigna
- Cardiovascular Biology, International Centre for Genetic Engineering and Biotechnology
- DOI
- https://doi.org/10.1038/s41467-021-27622-9
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
Here the authors show that a monoclonal antibody against a soluble isoform of Bone Morphogenetic Protein 1 prevents cardiac cell death, reducing fibrosis and preserving cardiac function after myocardial ischemia.
